This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 594Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
---|---|---|---|---|---|---|---|---|---|
2301 | GAPD | RNAs | Human | Upregulated in HCV associated HCC (v/s normal samples with fold change 5.27) and (ratio of HBV-HCC v/s HCV-HCC 0.29) | Diagnostic | HCV associated HCC v/s normal and HBV associated HCC | p < 0.05 | Tissue | 18932288 |
2302 | CD58 | RNAs | Human | Upregulated in HCV associated HCC (v/s normal samples with fold change 4.68) and (ratio of HBV-HCC v/s HCV-HCC 0.31) | Diagnostic | HCV associated HCC v/s normal and HBV associated HCC | p < 0.05 | Tissue | 18932288 |
2303 | CD24 | RNAs | Human | Upregulated in the high-risk group | Prognostic | Early recurrence of HCC v/s Late recurrence of HCC | p < 0.001 | Tissue | 18381945 |
2304 | CLDN10 | RNAs | Human | Upregulated in Cirrhosis v/s control and early and advanced HCC | Diagnostic | Cirrhosis v/s Low/High grade dysplastic nodules, normal and early/Late HCC | p < 0.05 | Tissue | 17393520 |
2305 | GREM2 | RNAs | Human | Upregulated in dysplasia v/s control and early/advanced HCC | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
2306 | EPO | RNAs | Human | Upregulated in dysplasia v/s control and early/advanced HCC | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
2307 | NRG1 | RNAs | Human | Upregulated in dysplasia v/s control and early/advanced HCC | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
2308 | ASPM | RNAs | Human | Upregulated in early/advanced HCC v/s control and dysplasia | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
2309 | PRIM1 | RNAs | Human | Upregulated in early/advanced HCC v/s control and dysplasia | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
2310 | HMMR | RNAs | Human | Upregulated in early/advanced HCC v/s control and dysplasia | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
2311 | IRAK1 | RNAs | Human | Upregulated in early/advanced HCC v/s control and dysplasia | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
2312 | C/EBP | RNAs | Human | Downregulated in cancer | Diagnostic | HCC v/s non-tumor HCC | NA | Tissue | 11306505 |
2313 | HNF-1 | RNAs | Human | Upregulated in cancer | Diagnostic | HCC v/s non-tumor HCC | NA | Tissue | 11306505 |
2314 | HNF-3beta | RNAs | Human | Upregulated in cancer | Diagnostic | HCC v/s non-tumor HCC | NA | Tissue | 11306505 |
2315 | HNF-4alpha | RNAs | Human | Upregulated in cancer | Diagnostic | HCC v/s non-tumor HCC | NA | Tissue | 11306505 |
2316 | HNF-4gamma | RNAs | Human | Upregulated in cancer | Diagnostic | HCC v/s non-tumor HCC | NA | Tissue | 11306505 |
2317 | NDRG2 | Protein and RNAs | Human | Downregulated in HCC than non-tumor | Diagnostic and Prognostic | HCC v/s cirrhosis/healthy/non-tumor HCC; associated with recurrence and tumor grade | p < 0.05 | Tissue | 18519680 |
2318 | CSTB | Protein and RNAs | Human | Upegulated in HCC than non-tumor | Diagnostic | HCC v/s cirrhosis/healthy/non-tumor HCC | p < 0.05 | Serum | 18281540 |
2319 | AFP | Protein | Human | Upegulated in HCC than non-tumor | Diagnostic | HCC v/s cirrhosis/healthy/non-tumor HCC | p < 0.05 | Serum | 18281540 |
2320 | CSTB, AFP | Protein | Human | Upegulated in HCC than non-tumor | Diagnostic | HCC v/s cirrhosis/healthy/non-tumor HCC | p < 0.05 | Serum | 18281540 |
2321 | TGF beta | RNAs | Human | Upegulated in HCC than non-tumor | Prognostic | early occurrence v/s late recurrence | NA | Tissue | 20380719 |
2322 | Myc | RNAs | Human | Upegulated in HCC than non-tumor | Prognostic | early occurrence v/s late recurrence | NA | Tissue | 20380719 |
2323 | LOC388796, A_32_P406142, SAFB, MKL1, TNKS1BP1, PMM2, PPP2R5C, SAFB2, GATA4, RASD1, KIAA1967, | RNAs | Human | over expressed in subjects with fastest recurrence | Prognostic | early occurrence v/s late recurrence | p < 0.0001 | Tissue | 20380719 |
2324 | ID2 | Protein and RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.4) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.005 | Tissue | 17088983 |
2325 | API5 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.49) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2326 | CTAG1 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.36) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2327 | NOLA2 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.34) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2328 | DKFZP566D193 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.3) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2329 | IMMT | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.3) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2330 | DDX1 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.16) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2331 | NUDC | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.14) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2332 | HT010 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.14) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2333 | RAN | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.14) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2334 | PDHB | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.13) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2335 | SCA1 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.12) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2336 | PTENP1 | RNAs | Human | Upregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.11) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2337 | HFL3 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 2.0) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2338 | PMS2L11 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.83) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2339 | SGK | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.64) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2340 | GPRK6 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.59) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2341 | ZNF216 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.54) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2342 | TIAL1 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.53) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2343 | KIAA0564 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.48) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2344 | GADD45B | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.41) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2345 | TAPBP | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.35) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2346 | RHO6 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.25) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2347 | SLC9A3R2 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.23) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2348 | HFL1 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.23) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2349 | CG018 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.23) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |
2350 | PIK3R1 | RNAs | Human | Downregulated in HCCs with PVI in comparison with HCCs without PVI (with Fisher ratio 1.22) | Prognostic | HCC with PVI v/s HCC without PVI | p < 0.05 | Tissue | 17088983 |